AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security |
The 2016 annual meeting of stockholders for Aytu BioScience, Inc.
for the fiscal year ended June 30, 2016 was held on November 15,
2016. Of the 5,080,591 shares outstanding on the record date for
the meeting, a total of 3,825,030 shares were present or
represented at the meeting.
At the meeting, our stockholders elected five members to our
board of directors as follows:
| Members | Number of Shares Voted For |
Number of Shares Withheld (Includes Abstentions) |
Broker Non-Votes |
| Gary V. Cantrell | 2,698,093 | 33,988 | 1,092,949 |
| Joshua R. Disbrow | 2,675,629 | 56,452 | 1,092,949 |
| Carl C. Dockery | 2,673,683 | 58,398 | 1,092,949 |
| John A. Donofrio, Jr. | 2,698,076 | 34,005 | 1,092,949 |
| Michael Macaluso | 2,673,427 | 58,654 | 1,092,949 |
The election of directors was determined by a plurality of the
votes cast at the meeting, whereby the five nominees receiving
the highest number of FOR votes were elected as directors.
At the meeting, our stockholders took the following actions:
|
Approved, by a majority of the shares of our outstanding capital stock, an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number between 1-for-2 and 1-for-4, as determined by the board of directors, at any time before November 15, 2017, if and as determined by the board of directors. The vote for such approval was 3,504,083 shares for, 310,053 shares against, 10,894 shares abstaining, and no shares of broker non-votes; |
|
Approved, by a majority of the shares voting at the meeting, amendments to our 2015 Stock Option and Incentive Plan to (i) increase the number of authorized shares of common stock reserved for issuance thereunder from 833,334 shares to 2,000,000 shares, (ii) increase the number of shares that may be issued as incentive stock options from 833,334 shares to 2,000,000 shares, and (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted to any one individual that is intended to qualify as performance-based compensation under Section162(m) of the Internal Revenue Code of 1986, as amended, for any performance cycle, in each case from 166,667 shares to 1,000,000 shares. The vote for such approval was 2,360,026 shares for, 370,957 shares against, 1,098 shares abstaining, and 1,092,949 shares of broker non-votes; and |
|
Ratified, by a majority of the shares voting at the meeting, the appointment of EKSH, LLLP as our independent registered public accounting firm for the fiscal year ending June 30, 2017. The vote for such approval was 3,757,747 shares for, 25,898 shares against, 41,385 shares abstaining, and no shares of broker non-votes. |
About AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Recent Trading Information
AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) closed its last trading session up +0.03 at 1.26 with 41,294 shares trading hands.